Evaluation of the outcomes in patients with chronic myeloid leukemia treated with imatinib in 18-year follow-up
The objective of this paper is to examine the effects of Imatinib on patients who are at the chronic phase of chronic myeloid leukemia (CML). Method: Totally, 79 patients with CML who received the treatment between 2003 and 2020 entered the study. The patients were evaluated in terms of molecular re...
Main Authors: | Mozafar Aznab, Ali Shahriari-Ahmadi, Fatemeh Heydarpour |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Leukemia Research Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048921000388 |
Similar Items
-
A case of double leukemia: chronic myeloid leukemia intolerant to imatinib and chronic lymphocytic leukemia
by: Miriana Rocchi
Published: (2015-10-01) -
Imatinib resistance was reversed by nilotinib in the acute transformation of chronic myeloid leukemia: A case report
by: Meng Xiao, et al.
Published: (2017-12-01) -
Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome
by: Massimo Breccia
Published: (2015-10-01) -
Efficacy of nilotinib therapy in patient with CML diagnosed in pre-TKI era and resistant to imatinib
by: Ivana Pierri, et al.
Published: (2015-10-01) -
Nilotinib after imatinib failure
by: Luca Pezzullo
Published: (2015-10-01)